Silybin has therapeutic efficacy against non-small cell lung cancer through targeting of Skp2

Announcing a new review article publication for Acta Materia Medica journal. Silybin (SB), a natural flavonoid isolated from Silybum marianum, has been used to treat hepatic fibrosis in clinical settings and as a dietary supplement, because of its hepatoprotective potential. Numerous studies have shown that SB also exerts promising anticancer effects; however, the anticancer targets of SB and the underlying mechanism were unclear. The authors of this article found that SB significantly inhibited the proliferation of non-small cell lung cancer without causing cytotoxicity toward normal Beas-2B bronchial epithelial cells. Mechanistically, SB binds the F-box protein Skp2 and disrupts Skp1-Skp2 interaction, thereby decreasing Skp2 protein levels, inducing accumulation of Skp2 substrates, and leading to G1-phase cell-cycle arrest and the suppression of cell migration. In lung orthotopic xenografts, SB also significantly decreased Skp2 expression and increased p27/Kip1 protein levels. SB administration inhibited tumor growth and metastasis in lung tissue, thus prolonging survival time in mice without causing obvious toxicity. Thus, SB is a potential Skp2-targeting agent that warrants further clinical investigation.

Article Reference: Shi-Bing Zhang, Ming Hong and Xiao-Yang Sun et al. Silybin has therapeutic efficacy against non-small cell lung cancer through targeting of Skp2. Acta Materia Medica. Vol. 1(3):302-313. DOI: 10.15212/AMM-2022-0011

Keywords: silybin, NSCLC, Skp2, p27, cell-cycle arrest

Acta Materia Medica welcomes the submission of research articles, review articles, databases, mini reviews, commentaries, editorials, short communications, case report articles and study protocols.

Submission Process

Submissions to Acta Materia Medica are made using ScholarOne, the online submission and peer review system. Registration and access are available at

Queries about the journal can be sent to

Please visit to learn more about the journal.

Editorial Board:

There are no author submission or article processing fees.

Follow Acta Materia Medica on Twitter; Facebook (

eISSN 2737-7946